Plerixafor

Drug Profile

Plerixafor

Alternative Names: AMD 3100; JM 3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Chronic lymphocytic leukaemia; Glioma; Myocardial infarction; Sickle cell anaemia
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 09 Dec 2017 Interim adverse events and pharmacodynamics data from a phase I trial in Stem cell mobilisation presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in France (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top